Dynavax Technologies Corporation (LON:0IDA)
London
· Delayed Price · Currency is GBP · Price in USD | Market Cap | 903.07M |
| Revenue (ttm) | 228.03M |
| Net Income (ttm) | -46.49M |
| Shares Out | n/a |
| EPS (ttm) | -0.36 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 36 |
| Average Volume | 362 |
| Open | 9.86 |
| Previous Close | 10.13 |
| Day's Range | 9.83 - 9.86 |
| 52-Week Range | 9.34 - 14.56 |
| Beta | 1.04 |
| RSI | 49.71 |
| Earnings Date | Aug 7, 2025 |
About Dynavax Technologies
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States and internationally. The company offers HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults aged 18 years and older; and CpG 1018, the adjuvant used in HEPLISAV-B. It also develops rF1V, a plague vaccine candidate in Phase 2 clinical trial; and Z-1018, an investigational vaccine candidate in Phase 1/2 clinical trial for the pr... [Read more]
News
Dynavax re-elects all board members, despite Deep Capital's push to change
Dynavax elects all four of its nominees after Deep Track proxy fight
Biopharmaceutical company Dynavax Technologies on Wednesday defeated investment firm Deep Track Capital's effort to unseat directors when investors re-elected all four candidates, the company said.
Dynavax Stockholders Elect All Dynavax Director Nominees at 2025 Annual Meeting
EMERYVILLE, Calif. , June 11, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical company developing and commerciali...
Deep Track Capital Sends Letter to Dynavax Technologies Shareholders Offering Final Perspectives on Why Change is Needed in the Boardroom
GREENWICH, Conn.--(BUSINESS WIRE)--Deep Track Capital, LP, (together with its affiliates, “Deep Track” or “we”), one of the largest shareholders of Dynavax Technologies Corporation (NASDAQ: DVAX) (“Dy...
Dynavax Urges Stockholders to Support Its Director Nominees at June 11 Annual Meeting
Dynavax's Strategy is Delivering Significant Long-Term Stockholder Value Dynavax's Nominees Are Vastly Superior to Deep Track's Candidates Across Every Critical Area Follow Recommendations of Proxy Ad...
Dynavax responds to proxy advisor calling for board change
Dynavax Comments on Glass Lewis Recommendation
Dynavax is Already Delivering Significant Long Term Stockholder Value Through Execution of Current Strategy Overseen by Board; Deep Track's Inferior Short-Term Plan and Nominees are Not in the Best In...
Glass Lewis Recommends Shareholders Support Deep Track's Case for Board Change at Dynavax Technologies
GREENWICH, Conn.--(BUSINESS WIRE)--Deep Track Capital, LP, (together with its affiliates, “Deep Track” or “we”), one of the largest shareholders of Dynavax Technologies Corporation (NASDAQ: DVAX) (“Dy...
Dynavax to Present at William Blair's 45th Annual Growth Stock Conference
EMERYVILLE, Calif. , May 28, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, toda...
Deep Track Capital Comments on ISS Recommendation
GREENWICH, Conn.--(BUSINESS WIRE)--Deep Track Capital, LP, (together with its affiliates, “Deep Track” or “we”), one of the largest shareholders of Dynavax Technologies Corporation (NASDAQ: DVAX) (“Dy...
ISS backs Dynavax directors in board fight with Deep Track Capital
Proxy advisory firm Institutional Shareholder Services urged Dynavax Technologies shareholders on Friday to reelect all its company directors instead of backing life sciences investment firm Deep Trac...
Leading Independent Proxy Advisory Firm ISS Recommends Stockholders Vote "FOR" All Four of Dynavax's Highly Qualified Director Nominees
ISS Recognizes There is No Case for Change Dynavax's Superior Strategy and Current Board are Best Equipped to Deliver Significant Long-Term Stockholder Value Dynavax Comments on Deep Track's Misleadin...
Dynavax Technologies: Hepatitis-B Vaccine Specialist Looking Good
Deep Track Capital Issues Letter to Fellow Dynavax Technologies Shareholders Detailing Critical Issues in Advance of Annual Meeting
GREENWICH, Conn.--(BUSINESS WIRE)--Deep Track Capital, LP, (together with its affiliates, “Deep Track” or “we”), one of the largest shareholders of Dynavax Technologies Corporation (NASDAQ: DVAX) (“Dy...
Dynavax Files Investor Presentation Highlighting Superior Strategy and Board That is Delivering Strong Financial Results and Significant Long-Term Value
Presentation Underscores Deep Track's Value Destructive Plan and Inferior Slate of Director Nominees Urges Stockholders to Vote "FOR" All Four Dynavax Director Nominees on the GOLD Proxy Card Today EM...
Dynavax Issues Statement and Mails Letter to Stockholders Emphasizing Record Financial Results and Continued Momentum
Deep Track's Misleading Investor Presentation Demonstrates its Single-Minded Approach to Abandon Long-Term Value Opportunities in Exchange for Short-Term Return Urges Stockholders to Vote "FOR" All Fo...
Decoding Dynavax Technologies Corp (DVAX): A Strategic SWOT Insight
Decoding Dynavax Technologies Corp (DVAX): A Strategic SWOT Insight
Dynavax signals strong start to 2025 with $305M-$325M revenue guidance and new vaccine programs
Dynavax Technologies Corporation (DVAX) Q1 2025 Earnings Call Transcript
Dynavax Technologies Corporation (NASDAQ:DVAX) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ETCompany ParticipantsPaul Cox - Vice President,...
Dynavax GAAP EPS of -$0.77, revenue of $68.16M misses by $0.23M
Dynavax Reports First Quarter 2025 Financial Results and Announces New Pipeline Programs
Record HEPLISAV-B® first quarter net product revenue of $65 million , representing 36% year-over-year growth Top-line results in Part 1 of Phase 1/2 shingles vaccine trial expected in Q3 2025 New pand...
Dynavax Reports First Quarter 2025 Financial Results and Announces New Pipeline Programs
Record HEPLISAV-B® first quarter net product revenue of $65 million, representing 36% year-over-year growth Top-line results in Part 1 of Phase 1/2 shingles vaccine trial expected in Q3 2025 New pande...
Deep Track Capital Releases Investor Presentation on Dynavax Technologies
GREENWICH, Conn.--(BUSINESS WIRE)--Deep Track Capital, LP, (together with its affiliates, “Deep Track” or “we”) one of the largest shareholders of Dynavax Technologies Corporation (NASDAQ: DVAX) (“Dyn...
Dynavax Q1 2025 Earnings Preview
Dynavax Announces Nationwide Harris Poll Survey Results Finding Americans Underestimate the Serious Consequences of Hepatitis B and Vaccine Protection Benefits
Over half of American adults do not know chronic hepatitis B can cause liver disease such as cirrhosis and liver cancer Half of American adults were unaware that anyone can be at risk for the hepatiti...